TScan Therapeutics, Inc.

NasdaqGM:TCRX Stock Report

Market Cap: US$119.7m

TScan Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:TCRX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
20 May 25BuyUS$3,106,553Lynx1 Capital Management LPCompany2,588,794US$1.20
13 Dec 24BuyUS$385,769Lynx1 Capital Management LPCompany131,800US$3.01
15 Nov 24BuyUS$4,114Lynx1 Capital Management LPCompany947US$4.34

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of TCRX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders429,2230.756%
Hedge Funds12,287,45421.7%
General Public15,763,22827.8%
Institutions28,268,08849.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 67.11% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.9%
Lynx1 Capital Management LP
7,857,347US$16.6m46.7%3.23%
12.4%
Baker Bros. Advisors LP
7,061,380US$14.9m0%0.1%
9.21%
BVF Partners L.P.
5,226,074US$11.0m6.88%0.36%
4.52%
BlackRock, Inc.
2,566,124US$5.4m-47.4%no data
3.79%
The Vanguard Group, Inc.
2,149,376US$4.5m-8.8%no data
3.68%
Propel Bio Management, LLC
2,087,139US$4.4m0%4.62%
2.19%
Deer Management Co. LLC
1,245,504US$2.6m0%0.11%
1.9%
GV Management Company, LLC
1,077,080US$2.3m0%0.27%
1.84%
Simplify Asset Management Inc.
1,046,916US$2.2m0%0.05%
1.57%
Aberdeen Group Plc
891,448US$1.9m0%no data
1.5%
Morgan Stanley
851,481US$1.8m57.1%no data
1.4%
Renaissance Technologies LLC
792,056US$1.7m367%no data
1.17%
Dean Capital Investments Management, LLC
665,563US$1.4m0%0.57%
1.11%
Millennium Management LLC
630,138US$1.3m173%no data
1.06%
Tang Capital Management, LLC
600,000US$1.3m0%0.05%
1%
Geode Capital Management, LLC
566,371US$1.2m-44.2%no data
0.82%
K2 HealthVentures
467,904US$987.3k0%no data
0.71%
UBS Asset Management AG
400,401US$844.8k224%no data
0.7%
The Goldman Sachs Group, Inc.
396,668US$837.0k199%no data
0.64%
Two Sigma Investments, LP
365,034US$770.2k305%no data
0.51%
JPMorgan Chase & Co.
287,743US$607.1k8.54%no data
0.39%
Citadel Advisors LLC
218,987US$462.1k303%no data
0.38%
Bank of America Corporation
217,967US$459.9k28%no data
0.38%
Two Sigma Advisers, LP
214,400US$452.4k338%no data
0.36%
Point72 Asset Management, L.P.
201,582US$425.3k845%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/05 22:20
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TScan Therapeutics, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Suranjit MukherjeeBTIG
Justin ZelinBTIG